Adagrasib is a inhibitor of KRASG12C, which is a notoriously difficult to treat cancerous mutation.

Product Info

Cas No. 2326521-71-3

Purity ≥99%

Formula C32H35ClFN7O2

Formula Wt. 604.13

IUPAC Name 2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile

Synonym MRTX-849

Appearance White powder

Shipping ａnd Storage

Store Temp  -20°C

Ship Temp  Ambient

艾美捷 LKT Labs 阿達格拉西布Adagrasib是KRASG12C的抑制劑，KRASG<>C是一種眾所周知的難以治療的癌性突變。

阿達格拉西布基礎信息：

編號：A121008

cas：2326521-71-3

純度：≥99%

公式：C32H35ClFN7O2

配方重量：604.13

IUPAC名稱：2-[（2S）-4-[7-（8-氯萘-1-基）-2-[[（2S）-1-甲基吡咯烷-2-基]甲氧基]-6，8-二氫-5H-吡啶并[3，4-d]嘧啶-4-基]-1-（2-氟丙基-2-烯�；┻哙�-2-基]乙腈

同義詞：MRTX-849

外觀：白色粉末

阿達格拉西布文獻參考：

Zhang Y, Li C, Xia C, et al. Adagrasib, a KRAS G12c inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro ａnd in vivo. Cell Commun Signal. 2022 Sep 14;20(1):142. PMID: 36104708

Sabari J, Velcheti V, Shimizu K, et al. Activity of adagrasib (MRTX849) in brain metastases: preclinical models ａnd clinical data from patients with KRASG12c-mutant non-small cell lung cancer. Clin Cancer Res. 2022 Aug 2;28(15):3318-3328. PMID: 35404402

Koga T, Suda K, Fujino T, et al. KRAS secondary mutations that confer acquired resistance to KRAS G12c inhibitors, sotorasib ａnd adagrasib, ａnd overcoming strategies: insights form in vitro experiments. J Thorac Oncol. 2021 Aug;16(8):1321-1332. PMID: 33971321

來源：https://www.amyjet.com/products/LKT-A121008-1mg.shtml